Dacogen

Dacogen is a brand name of decitabine, approved by the FDA in the following formulation(s):

DACOGEN (decitabine - injectable; intravenous)

• 
  Manufacturer: EISAI INC
  
  Approval date: May 2, 2006
  
  Strength(s): 50MG/VIAL ^[RLD]

Has a generic version of Dacogen been approved?

No. There is currently no therapeutically equivalent version of Dacogen available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dacogen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Dacogen.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 2, 2011 - NEW CHEMICAL ENTITY
  
  
  • March 11, 2013 - ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS
  
  
  • May 2, 2013 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Dacogen Consumer Information (Drugs.com)
• Dacogen Consumer Information (Wolters Kluwer)
• Dacogen Consumer Information (Cerner Multum)
• Dacogen Advanced Consumer Information (Micromedex)
• Dacogen AHFS DI Monographs (ASHP)
• Decitabine Consumer Information (Wolters Kluwer)
• Decitabine Consumer Information (Cerner Multum)
• Decitabine Intravenous Advanced Consumer Information (Micromedex)
• Decitabine AHFS DI Monographs (ASHP)